Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.01 (-0.32%)

    Market Cap: $10.17M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Intensity Therapeutics, Inc. Common stock (INTS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Intensity Therapeutics, Inc. Common stock are Marker Therapeutics (MRKR), Tempest Therapeutics (TPST) and Tscan Therapeutics (TCRX). By market cap, Intensity Therapeutics, Inc. Common stock ranks 8th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.

    Peer Comparison

    INTS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    In8bio Inc (INAB)$8.86MN/AN/A0.0%N/A0.0%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Dyadic International Inc (DYAI)$13.10MN/A4.4x-200.5%-224.8%-0.6%0.00%
    Citius Pharmaceuticals Inc (CTXR)$14.69MN/A1.9x0.0%-84.3%0.0%0.00%
    Peer median$10.62MN/A4.4x0.0%-139.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Intensity Therapeutics, Inc. Common stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors
    In8bio Inc (INAB)
    IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers...
    INAB competitors
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Dyadic International Inc (DYAI)
    Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States.
    DYAI competitors
    Citius Pharmaceuticals Inc (CTXR)
    Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products.
    CTXR competitors

    Frequently Asked Questions About INTS

    Who are Intensity Therapeutics, Inc. Common stock's main competitors?

    The companies most similar to Intensity Therapeutics, Inc. Common stock include Marker Therapeutics (MRKR), Tempest Therapeutics (TPST), Tscan Therapeutics (TCRX), GT Biopharma (GTBP) and In8bio (INAB), listed from the closest match.

    Who is Intensity Therapeutics, Inc. Common stock's biggest competitor?

    Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Marker Therapeutics (MRKR) is the closest match by business profile, size, sector and industry.

    How does INTS stock compare with its competitors?

    INTS' net margin is 0.0% against a peer median of 0.0%.

    Which of Intensity Therapeutics, Inc. Common stock's competitors pays a higher dividend?

    Intensity Therapeutics, Inc. Common stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Intensity Therapeutics, Inc. Common stock bigger than its competitors?

    No. Intensity Therapeutics, Inc. Common stock is 8th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.